Viatris's novel fast-acting meloxicam (MR-107A-02) met all primary and secondary endpoints in two pivotal Phase 3 trials for moderate-to-severe acute pain following herniorrhaphy and bunionectomy surgeries.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.